Huahao Zhongtian Pharmaceutical announced that the company's wholly-owned US subsidiary Biostar Pharma, Inc. has completed the first patient administration in an important overseas clinical study: UTD1 combined with capecitabine to treat HER2-negative breast cancer brain metastasis in the US. The study used a two-stage design, and a total of about 120 subjects were proposed. The main end point of the study was the objective response rate of the central nervous system.

Huahao Zhongtian Pharmaceutical announced that the company's wholly-owned US subsidiary Biostar Pharma, Inc. has completed the first patient administration in an important overseas clinical study: UTD1 combined with capecitabine to treat HER2-negative breast cancer brain metastasis in the US. The study used a two-stage design, and a total of about 120 subjects were proposed. The main end point of the study was the objective response rate of the central nervous system.